Jiangsu Huili Biotechnology
A Hong Kong-based next-generation synthetic biology enzyme computational design platform, completed its Series A financing round with hundreds of million RMB
About Jiangsu Huili Biotechnology
Jiangsu Huili Biotechnology Co., Ltd., also known as Huili Bio, operates as a high-tech enterprise centered on the application of synthetic biology. The company was established in 2018 and is headquartered in Taizhou, China, with a key research and development center located in Tianjin. The legal representative and chairman is Guo Hongming. The company's core team is composed of individuals from domestic universities, the Chinese Academy of Sciences, and other research institutions.
Huili Bio specializes in the research, development, and industrial application of biotechnology, focusing on the creation of industrial enzyme preparations. Its business model revolves around providing sustainable, bio-manufacturing solutions for various sectors, including pharmaceutical intermediates, animal health, functional foods, new materials, and environmental preservation. A significant milestone was achieved in July 2022, when the company secured hundreds of millions of RMB in a Series A financing round. This funding was co-led by Legend Capital and BioTrack Capital, with participation from others, and was earmarked for expanding large-scale production facilities, advancing the R&D of new product pipelines, and growing the team.
The company's principal offering is its proprietary artificial intelligence industrial enzyme computing design platform. This platform facilitates the computational design of enzyme components, which are crucial for synthetic biological reactions. It enables the company to develop and commercialize products with higher efficiency and lower costs compared to traditional chemical synthesis—reportedly reducing costs by nearly 30% and increasing yields by almost 70%. Through this technology, Huili Bio has developed over 10 products with independent intellectual property rights. Their product portfolio includes pharmaceutical intermediates such as Acamprosate and Oritavancin, as well as functional food ingredients and animal health products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 25.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2022 | $41M | $165M | ZWC Partners · Yunqi Partners · Cenova Capital · BioTrack Capital | ↗ |
Growth signals
Latest recorded traffic for Jiangsu Huili Biotechnology is 910 monthly website visits, up 506.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Jiangsu Huili Biotechnology in its local ecosystem
The Jiangsu Huili Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Legend Capital
ZWC Partners
Yunqi Partners
Cenova Capital
BioTrack Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jiangsu Huili Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jiangsu Huili Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







